miR-29a-3p/THBS2 Axis Regulates PAH-Induced Cardiac Fibrosis

Chih-Hsin Hsu1, I-Fan Liu2,3, Hsuan-Fu Kuo4,5,6,7

  • 1Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.

Insights

MicroRNA-29a-3p (miR-29a-3p) shows anti-fibrotic effects in pulmonary artery hypertension (PAH) by targeting thrombospondin-2 (THBS2). Lower miR-29a-3p and higher THBS2 levels indicate PAH progression and may serve as prognostic markers.

Area of Science:

  • Biomedical research
  • Cardiovascular pathology
  • Molecular biology

Background:

  • Pulmonary artery hypertension (PAH) is characterized by extracellular matrix (ECM) remodeling and cardiac fibrosis.
  • MicroRNA-29a-3p (miR-29a-3p) is known to regulate ECM in other fibrotic conditions, but its role in PAH-induced cardiac fibrosis is not well understood.
  • Thrombospondin-2 (THBS2) is an ECM protein implicated in fibrosis.

Purpose of the Study:

  • To investigate the role of miR-29a-3p in cardiac fibrosis progression in PAH.
  • To determine the relationship between miR-29a-3p and THBS2 expression in PAH.
  • To evaluate the diagnostic and prognostic value of miR-29a-3p and THBS2 in PAH.

Main Methods:

  • Assessed miR-29a-3p and THBS2 expression in cell culture, a monocrotaline-induced PAH mouse model, and human PAH patients.
  • Investigated the direct targeting of THBS2 by miR-29a-3p.
  • Correlated circulating levels of miR-29a-3p and THBS2 with PAH diagnostic parameters.

Main Results:

  • Circulating levels of miR-29a-3p were decreased, while THBS2 levels were increased in patients and mice with PAH.
  • miR-29a-3p directly targets THBS2, inhibiting its expression.
  • miR-29a-3p demonstrated a direct anti-fibrotic effect on PAH-induced cardiac fibrosis.
  • Circulating miR-29a-3p and THBS2 levels correlated with PAH diagnostic parameters, indicating prognostic value.

Conclusions:

  • miR-29a-3p acts as a direct regulator of THBS2 in PAH-induced cardiac fibrosis.
  • miR-29a-3p exhibits anti-fibrotic properties relevant to PAH.
  • Circulating miR-29a-3p and THBS2 hold potential as diagnostic and prognostic biomarkers for PAH, with miR-29a-3p showing therapeutic promise.